SPORE in Breast Cancer

乳腺癌中的孢子

• 批准号: 10456735
• 负责人: BEN H PARK
• 金额: $ 203.14万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-08-07 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10456735
• 关键词: Academic Medical Centers; Address; Advocate; Antigen Presentation; Antigen Targeting; Area; Atlases; Award; BRCA deficient; Basic Science; Bioinformatics; Biometry; Breast; Breast Cancer Patient; Breast Cancer Risk Factor; CDK4 gene; Cancer Center; Carboplatin; Cells; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; DNA Damage; Databases; Development; Diagnosis; Disease; Drug Combinations; ERBB2 gene; Ensure; Estrogen Antagonists; Estrogen Receptors; Estrogens; Evaluation; Fibroblast Growth Factor Receptors; Fulvestrant; Funding; Future; Genomics; Goals; Health; Human; Human Resources; Immune; Immune Evasion; Immune response; ImmunoPET; Immunophenotyping; Immunotherapeutic agent; Immunotherapy; In Vitro; Individual; Informatics; International; Investigation; MEK inhibition; MEKs; Mediating; Metastatic breast cancer; Modeling; Molecular Target; Mutate; Myelogenous; Neoplasms; PDL1 inhibitors; Paclitaxel; Pathology; Patient Selection; Patient-Focused Outcomes; Patients; Pharmaceutical Preparations; Poly(ADP-ribose) Polymerases; Positron-Emission Tomography; Prognosis; Refractory; Research Personnel; Research Project Grants; Resistance; Resource Sharing; Resources; Solid Neoplasm; Testing; Therapeutic; Therapeutic Clinical Trial; Therapeutic Intervention; Tissues; Translational Research; Tumor Immunity; Up-Regulation; Validation; Woman; Work; anti-PD-L1 therapy; anticancer research; base; biomarker identification; cancer immunotherapy; cancer subtypes; career; checkpoint therapy; chemotherapy; clinical investigation; drug discovery; experience; hormone therapy; immunoregulation; improved; improved outcome; inhibitor; inhibitor therapy; innovation; innovative technologies; insight; malignant breast neoplasm; mammary; meetings; member; men; molecular targeted therapies; mouse model; multidisciplinary; new therapeutic target; programs; recruit; resistance mechanism; response; response biomarker; translational goal; triple-negative invasive breast carcinoma; tumor; tumor microenvironment

PROJECT SUMMARY/ABSTRACT: OVERALL This is the third competing renewal application of the Vanderbilt-Ingram Cancer Center (VICC) SPORE in Breast Cancer. Using the well-established framework of a very active and strong multidisciplinary VICC Breast Cancer Program that is robustly supported by the SPORE mechanism, we have made significant progress in our current project period. Our highly successful Developmental Research Projects (DRP) and Career Enhancement Programs (CEP) continue to catalyze new ideas and new investigators in translational breast cancer research, including two projects in this continuing renewal. We are uniquely poised to complete the proposed work and to be even more productive in the years to come, thanks to an exceptional multidisciplinary program and established productive collaborations with other Breast Cancer Programs and SPOREs, as well as national and international collaborations. Our overall goal remains the same: To conduct collaborative, multidisciplinary and mechanism-based translational research that will have the highest possible impact for women and men with or at risk for breast cancer. After significant planning and internal and external advisory board evaluation, we propose four bi-directional translational projects addressing basic, translational and clinical research questions of importance in human breast cancer; Projects 1 and 2 are continuation projects, Projects 3 and 4 are new projects that have evolved from two CEP awards in the current funding cycle: Project 1 - Mechanisms of Resistance to Endocrine Therapy in ER+ Breast Cancer; Project 2 - Strategies to Improve Outcomes for TNBC Patients Integrating Subtype-specific Genomic and Immune-based Discoveries; Project 3 - Targeting the DNA Damage Response in Breast Cancer; Project 4 - Targeting Antigen Presentation to Improve Immunotherapy Responses in Breast Cancer. The application also includes DRP and CEP, and four highly integrated shared core resources: Administration and Engagement, Biostatistics and Bioinformatics, Pathology and Tissue Informatics, and Immunophenotyping. The cores bring innovative technology and resources, including additional personnel with project-specific expertise, to the overall VICC Breast SPORE Program and do not duplicate pre- existing shared resources available at VICC or Vanderbilt University Medical Center (VUMC). With a focus on human endpoints, six interventional therapeutic clinical trials are associated with the highly translational projects in this proposal, all based on extensive collaboration between world-class basic and clinical investigators. We have firmly established a true multidisciplinary team that successfully implements innovative clinical trials to test hypotheses that result from in vitro and patient studies, and that will continue to have productive translational collaborations with other Breast Cancer Programs and SPOREs as well as national and international groups.

项目摘要/摘要：总体 这是Vanderbilt-Ingram癌症中心（VICC）在乳房中的第三次竞争续约应用 癌症。使用一个非常活跃且强大的多学科VICC乳腺癌的框架 通过孢子机制支持的计划，我们在当前已经取得了重大进展 项目期。我们非常成功的发展研究项目（DRP）和职业增强 计划（CEP）继续催化新想法和转化乳腺癌研究中的新研究人员， 包括两个持续续订的项目。我们有独特的准备完成拟议的工作和 得益于一项卓越的多学科计划，在未来几年的生产力更高，并且 与其他乳腺癌计划和孢子以及国家以及国家和国家建立了生产性合作 国际合作。我们的总体目标保持不变：进行合作，多学科和 基于机制的转化研究将对有OR或 有乳腺癌的风险。经过大量计划以及内部和外部咨询委员会的评估，我们 提出四个双向翻译项目，解决基本，翻译和临床研究问题 在人类乳腺癌中的重要性；项目1和2是延续项目，项目3和4是新的 从当前资金周期中的两个CEP奖项演变的项目：项目1-机制 ER+乳腺癌中内分泌疗法的耐药性；项目2-改善TNBC结果的策略 整合亚型特异性基因组和免疫发现的患者；项目3-针对DNA 乳腺癌的损害反应；项目4-针对抗原表现以改善免疫疗法 乳腺癌的反应。该应用程序还包括DRP和CEP，以及四个高度集成的共享 核心资源：行政和参与，生物统计学和生物信息学，病理和组织 信息学和免疫表型。核心带来创新的技术和资源，包括其他 具有特定于项目专业知识的人员，整个VICC乳腺孢子计划，并且不重复 现有的共享资源可在VICC或Vanderbilt大学医学中心（VUMC）获得。专注于 人类终点，六个介入的治疗临床试验与高度转化的项目有关 在该提案中，所有这些都基于世界一流的基本研究人员和临床研究人员之间的广泛合作。我们 已经牢固建立了一个真正的多学科团队，该团队成功实施创新的临床试验进行测试 由体外和患者研究导致的假设，这将继续具有生产力的翻译 与其他乳腺癌计划和孢子以及国家和国际团体的合作。